Viveve completes 12-month post-treatment follow-up visits in PURSUIT trial

Viveve announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence, or SUI, in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month follow-up visits. A 17.6% loss-to-follow-up occurred, which is within the range anticipated for the trial. Upon completion of clinical data monitoring and analyses in the coming weeks, the company expects to present topline primary efficacy results from the PURSUIT trial in January 2023. If positive, the results may support a marketing application for a potential new SUI indication for Viveve’s dual-energy, noninvasive, single-session treatment in the U.S.